Table 3 Summary of Published Series of Patients with Severe Kawasaki Disease Treated with Cyclophosphamide
From: Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms
Article | # of pnts | Age at Dx | Sex | CYC dose | Route | CYC duration | Prior Tx | Follow up | Outcome |
|---|---|---|---|---|---|---|---|---|---|
Wallace CA et al, 2000 [9] | 2 | 0.9 yr, 2.7 yrs. | Male | 2 mg/kg/day | IV then PO | 1.5-7mo | IVIG, IVMP | 2.5 yr and 2.8 yrs. | Normal CAs at last follow up |
Lucron H et al, 2004 [10] | 4 | 0.3 yr, 0.8 yr, 2 yrs., 4.3 yrs | 50% Male | 10 mg/kg/day IV, then 2 mg/kg/day PO | IV then PO | IV 2–5 days, PO 6-12mo | IVIG, Plasma-pheresis | 8 yrs. and 13 yrs | 2/4 deceased, both with myocarditis and CAAs |
Briceno-Medina M et al, 2016 [11] | 1 | 12 yrs. | Male | 15 mg/kg/day | IV | 4 doses | IVIG, IVMP | 3 yrs. | + CAA, no stenosis or thrombosis |
Current series, 2020 | 10 | Median 2 yrs | 50% Male | 10 mg/kg/dose | IV | 1–2 doses | IVIG, IVMP, IFX, CsA, ANA | Median 2 yrs. 4mo | Mean (median) z scores at last follow up: LAD 7.5 (5.0), RCA 8.3 (6.0) |